Please note that the details of this Challenge are no longer open. This challenge is awarded and is no longer accepting new submissions. You can:
Challenge <p> Overcoming Key Burden Factors of Patient Participation in Clinical Trials</p>

Overcoming Key Burden Factors of Patient Participation in Clinical Trials

STATUS: Awarded
Active Solvers: 218
Posted: Nov 29 2016
Challenge ID: 9933940
 
Team Project Rooms are available on this Challenge. Team Share Challenge Share
Abstract

Deciding to participate in a clinical trial is a complex decision that requires a patient to weigh the pros and cons of potential medical benefit vs. the unknown risks of side effects plus the time, effort and commitment needed to comply with the study protocol. Once in a clinical trial, the burdens of participation may lead to excessive physical and mental stress, which can adversely affect the patient’s well-being and could cause him or her to drop out of a trial prematurely or prevent him or her from enrolling in additional studies. Allergan is committed to improving the patient experience and therefore desires new approaches to overcome key burdens associated with clinical trial participation.

This is an Ideation Challenge with a guaranteed award for at least one submitted solution.

Overview

Clinical trials are required in order to test the safety and efficacy of drug candidates and medical devices before they are approved for widespread use. In large part, the outcome of a clinical trial depends not only on the study design, which focuses upon the best way to answer a scientific question, but also upon the compliance of the volunteers who take part in the study. Little is actually known about how study participants make their decisions with regards to benefits and burdens, yet these choices ultimately affect the recruitment and retention rates in clinical trials. Allergan is attuned to patients’ needs and recognizes the importance of alleviating their burdens, especially when they are faced with difficult choices during a clinical trial.

This is an Ideation Challenge, which has the following unique features:

  • There is a guaranteed award.  The award(s) will be paid to the best submission(s) as solely determined by the Seeker. The total payout will be $20,000, with at least one award being no smaller than $5,000 and no award being smaller than $2,000.
  • The Solvers are not required to transfer exclusive intellectual property rights to the Seeker.  Rather, by submitting a proposal, the Solver grants to the Seeker a royalty-free, perpetual, and non-exclusive license to use any information included in this proposal, including for promotional purposes.

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on January 5, 2017. 

Late submissions will not be considered.

After the Challenge deadline, the Seeker will complete the review process and make a decision with regards to the Winning Solution(s). All Solvers that submit a proposal will be notified on the status of their submissions; however, no detailed evaluation of individual submissions will be provided.

ABOUT THE SEEKER

Allergan plc, headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, their R&D model, which defines their approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Allergan’s success is powered by more than 16,000 global colleagues’ commitment to be Bold for Life. Together, they build bridges, power ideas, act fast and drive results for customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information visit Allergan’s website at www.Allergan.com.

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is an InnoCentive Ideation™ Challenge?

An InnoCentive Ideation™ Challenge is a broad question formulated to obtain access to new ideas, similar to a global brainstorm for producing a breakthrough idea or market survey which may include ideas for a new product line, a new commercial application for a current product, or even a viral marketing idea to recruit new customers. Ideation™ Challenge submissions are typically about two written pages, and Seekers receive a non-exclusive, perpetual license to use all submissions.

In an Ideation™ Challenge, Solvers may:

  • Submit ideas of their own
  • Submit third party information that they have the right to use and further the authority to convey that right and the right to use and develop derivative works to Seekers
  • Submit information considered in the public domain without any limitations on use

Solvers should not reveal any confidential information in their submissions. Often the Ideation™ Challenge will be followed by one or more of the other three Challenge types to further develop the ideas and gain Intellectual Property protection when the concept has been well-defined.

Share This Challenge
InnoCentive Trust Partners